The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

Saved in:

Bibliographic Details
Main Authors:	Genta Iwamoto, Takashi Kawahara, Yumiko Yokomizo, Yasuhide Miyoshi, Masahiro Yao, Hiroji Uemura
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	Asian Journal of Urology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214388220300321
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer
by: Sat Prasad Nepal, et al.
Published: (2023-04-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

Initial Experience of Contact Laser Vaporization of the Prostate (CVP) for Benign Prostate Hyperplasia Patients With Hemorrhagic Risk
by: Yushi Araki, et al.
Published: (2024-01-01)

Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer
by: Yuxuan Chen, et al.
Published: (2025-01-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
by: Ying Zhang, et al.
Published: (2025-01-01)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
by: Jae Hoon Chung, et al.
Published: (2021-01-01)

Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer
by: Mike Wenzel, et al.
Published: (2025-07-01)

Neutrophil-and-monocyte-to-lymphocyte ratio is positively associated with elevated prostate-specific antigen levels and high-risk prostate cancer: evidence from the NHANES (2003–2008)
by: Shang Gao, et al.
Published: (2025-04-01)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
by: Jae Hoon Chung, et al.
Published: (2022-01-01)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
by: Yutaka Yamamoto, et al.
Published: (2018-01-01)

Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer
by: Chia-Hsien Shih, et al.
Published: (2025-03-01)

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
by: Naoya Nagaya, et al.
Published: (2020-01-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review
by: Stefano Salciccia, et al.
Published: (2024-04-01)

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer
by: Emmanuel S. Akinboye, et al.
Published: (2019-01-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Role of exosomes in castration-resistant prostate cancer
by: Yuan Cao, et al.
Published: (2025-05-01)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
by: Lu Tang, et al.
Published: (2016-01-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
by: Teresa Maria Santos Amaral, et al.
Published: (2012-01-01)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
by: Andrew Meyer, et al.
Published: (2012-01-01)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)

Utility of neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, mean platelet volume–platelet count ratios: Diagnostic and prognostic markers in patients with hepatocellular carcinoma, prostate carcinoma, stomach carcinoma, and aplastic anemia
by: V S Srikanth, et al.
Published: (2019-01-01)

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
by: Alexander W Wyatt, et al.
Published: (2015-04-01)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
by: Takuya Koie, et al.
Published: (2020-01-01)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
by: Jesal C. Patel, et al.
Published: (2013-01-01)

THERAPY WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: K. Y. Kanukoev, et al.
Published: (2015-04-01)

New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01)

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
by: Kazuhiro Nagao, et al.
Published: (2016-01-01)

Performance of free prostate-specific antigen ratio in differentiating between prostatic cancer and benign prostatic lesions at a referral hospital in South Africa
by: Boitumelo Phiri-Ramongane, et al.
Published: (2018-08-01)

Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
by: Shawn Du, et al.
Published: (2025-07-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

The preoperative neutrophil‐to‐lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy
by: Zhi Cao, et al.
Published: (2019-03-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Prenylated Chalcones as Anticancer Agents Against Castration-Resistant Prostate Cancer
by: Marcos Morales-Reyna, et al.
Published: (2025-06-01)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
by: Belinda Nghiem, et al.
Published: (2016-10-01)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
by: Matthew E. Pollard, et al.
Published: (2017-01-01)

PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES
by: K. M. Nushko, et al.
Published: (2015-10-01)

NASP implication in the androgen receptor associated with castration resistance in prostate cancer
by: Yun Feng, et al.
Published: (2025-07-01)